Periodontitis is an inflammatory disease triggered by host immune response to pathogenic microorganisms in the periodontal biofilm, leading to the loosening and subsequent loss of teeth, and increased risk for the development of various systemic conditions. Current treatments do not offer complete amelioration of periodontal tissue destruction because they do not directly address the biological causes of periodontal pathogenesis -- unbalanced, overly aggressive immune responses. There is compelling interest in developing targeted immunological interventions to treat periodontitis before it progresses to an expensive and refractory disease. B cells with a regulatory function (BREG) play a key role in immune system balance, restraining the excessive inflammatory responses by inhibiting pro-inflammatory cytokines and promoting regulatory T cell differentiation. The goal of this project is to characterize in vitro activated and expanded BREG in response to Toll-like receptor (TLR) agonists and co-stimulatory molecules, and to test these BREG to ameliorate periodontal bone resorption in vivo in a mouse model of experimental periodontal disease. We will then characterize the phenotype and immune regulatory function of human BREG in vitro using human peripheral blood mononuclear cells (PBMC) and gingival mononuclear cells (GMC). The central hypothesis of this project is that enhancing local BREG function can reduce immune-mediated periodontal disease bone loss. The three related and overlapping specific aims are: 1) Determine the activation and expansion of BREG from mouse spleen and intraperitoneal cavity and characterize the phenotypic markers that can be used to define such populations. The focus will be the interactions among multiple TLRs (TLR2, 4 and 9) on the activation of BREG and how such BREG be expanded in vitro. 2) Evaluate in vivo trafficking and the effects of adoptively transferred BREG on periodontal bone resorption using a mouse model of periodontal disease. Particular emphasis will be on the effect of transferred BREG on the RANKL production in local inflamed gingival tissues. 3) Characterize in vitro activated and expanded human BREG from PBMC of healthy and diseased individuals and more definitively, evaluate the effectiveness of the proposed regimes on GMC from periodontitis patients. Study of GMC associated with ongoing disease will enable us to determine the effect of the most promising regimens on BREG in a manner similar to treatment during disease, as the first step towards translational applications. Successful completion of this project would be expected to pave the way for translational research to delineate BREG-directed amelioration of periodontitis pathogenesis due to the unbalanced, overly aggressive immune responses. Novel strategies to selectively promote local BREG function may enable therapeutics to effectively treat patients with periodontal diseases that are resistant to current therapy.
According to recent findings from the Centers for Disease Control and Prevention (CDC), one out of every two American adults aged 30 and over (64.7 million) has mild, moderate or severe periodontitis, the more advanced form of periodontal disease. If untreated, it can cause jaw bone destruction and ultimately leading to tooth loss. The expenditures for treating these conditions far exceed $10 billion/year in the US. Current treatments do not offer complete amelioration of bone loss around teeth because they do not directly address the biological causes of periodontal bone loss -- unbalanced, overly aggressive host immune responses. This application will provide us new knowledge about balancing host immune response in periodontal disease by promoting immune regulatory functions and will contribute to development of local therapeutic strategies that are effective in preventing tooth loss in people with periodontal disease.
|Jiang, Shaoyun; Hu, Yang; Deng, Shu et al. (2018) miR-146a regulates inflammatory cytokine production in Porphyromonas gingivalis lipopolysaccharide-stimulated B cells by targeting IRAK1 but not TRAF6. Biochim Biophys Acta Mol Basis Dis 1864:925-933|
|Yu, X; Hu, Y; Freire, M et al. (2018) Role of toll-like receptor 2 in inflammation and alveolar bone loss in experimental peri-implantitis versus periodontitis. J Periodontal Res 53:98-106|
|Zhao, Qian; Hu, Yang; Deng, Shu et al. (2018) Cytidine-phosphate-guanosine oligodeoxynucleotides in combination with CD40 ligand decrease periodontal inflammation and alveolar bone loss in a TLR9-independent manner. J Appl Oral Sci 26:e20170451|
|Lin, Mei; Hu, Yang; Wang, Yuhua et al. (2017) Different engagement of TLR2 and TLR4 in Porphyromonas gingivalis vs. ligature-induced periodontal bone loss. Braz Oral Res 31:e63|
|Wang, Yuhua; Yu, Xiaoqian; Lin, Jiang et al. (2017) B10 Cells Alleviate Periodontal Bone Loss in Experimental Periodontitis. Infect Immun 85:|
|Liu, Zhiqiang; Hu, Yang; Yu, Pei et al. (2017) Toll-like receptor agonists Porphyromonas gingivalis LPS and CpG differentially regulate IL-10 competency and frequencies of mouse B10 cells. J Appl Oral Sci 25:90-100|
|Yu, Pei; Hu, Yang; Liu, Zhiqiang et al. (2017) Local Induction of B Cell Interleukin-10 Competency Alleviates Inflammation and Bone Loss in Ligature-Induced Experimental Periodontitis in Mice. Infect Immun 85:|
|Hu, Yang; Yu, Pei; Yu, Xinbo et al. (2017) IL-21/anti-Tim1/CD40 ligand promotes B10 activity in vitro and alleviates bone loss in experimental periodontitis in vivo. Biochim Biophys Acta Mol Basis Dis 1863:2149-2157|
|Shi, J; Liu, Z; Kawai, T et al. (2017) Antibiotic administration alleviates the aggravating effect of orthodontic force on ligature-induced experimental periodontitis bone loss in mice. J Periodontal Res 52:725-733|
|Yu, Xiaoqian; Wang, Yuhua; Lin, Jiang et al. (2016) Lipopolysaccharides-Induced Suppression of Innate-Like B Cell Apoptosis Is Enhanced by CpG Oligodeoxynucleotide and Requires Toll-Like Receptors 2 and 4. PLoS One 11:e0165862|
Showing the most recent 10 out of 14 publications